CU24352B1 - DERIVADOS DE ISOINDOLINA O ISOQUINOLINA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS DE Bcl-2 EN EL TRATAMIENTO DE CÁNCERES Y ENFERMEDADES AUTOINMUNES Y DEL SISTEMA INMUNITARIO, Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN - Google Patents

DERIVADOS DE ISOINDOLINA O ISOQUINOLINA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS DE Bcl-2 EN EL TRATAMIENTO DE CÁNCERES Y ENFERMEDADES AUTOINMUNES Y DEL SISTEMA INMUNITARIO, Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN

Info

Publication number
CU24352B1
CU24352B1 CUP2016000010A CU20160010A CU24352B1 CU 24352 B1 CU24352 B1 CU 24352B1 CU P2016000010 A CUP2016000010 A CU P2016000010A CU 20160010 A CU20160010 A CU 20160010A CU 24352 B1 CU24352 B1 CU 24352B1
Authority
CU
Cuba
Prior art keywords
antiapoptotic
bcl
inhibitors
useful
pharmaceutical compositions
Prior art date
Application number
CUP2016000010A
Other languages
English (en)
Spanish (es)
Other versions
CU20160010A7 (es
Inventor
Paul Brough
I-Jen Chen
James Edward Paul Davidson
Nanteuil Guillaume De
Mark Dodsworth
Imre Fejes
Olivier Geneste
Anne-Françoise Guillouzic
Jean-Michel Henlin
András Kotschy
Diguarher Thierry Le
Tiran Arnaud Le
Johannes W G Meissner
James Brooke Murray
Miklós Nyerges
Jérôme-Benoît Starck
Zoltán Szlávik
János Tatai
Claire Walmsley
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CU20160010A7 publication Critical patent/CU20160010A7/es
Publication of CU24352B1 publication Critical patent/CU24352B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CUP2016000010A 2013-07-23 2014-07-22 DERIVADOS DE ISOINDOLINA O ISOQUINOLINA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS DE Bcl-2 EN EL TRATAMIENTO DE CÁNCERES Y ENFERMEDADES AUTOINMUNES Y DEL SISTEMA INMUNITARIO, Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN CU24352B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2014/065764 WO2015011164A1 (en) 2013-07-23 2014-07-22 New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
CU20160010A7 CU20160010A7 (es) 2016-06-29
CU24352B1 true CU24352B1 (es) 2018-07-05

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000010A CU24352B1 (es) 2013-07-23 2014-07-22 DERIVADOS DE ISOINDOLINA O ISOQUINOLINA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS DE Bcl-2 EN EL TRATAMIENTO DE CÁNCERES Y ENFERMEDADES AUTOINMUNES Y DEL SISTEMA INMUNITARIO, Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN

Country Status (49)

Country Link
US (3) US9809574B2 (xx)
EP (1) EP3024826B1 (xx)
JP (1) JP6395829B2 (xx)
KR (1) KR102008431B1 (xx)
CN (2) CN109456324B (xx)
AP (1) AP2016008989A0 (xx)
AR (1) AR097009A1 (xx)
AU (1) AU2014295101B2 (xx)
BR (1) BR112016001080B1 (xx)
CA (1) CA2919572C (xx)
CL (1) CL2016000148A1 (xx)
CR (1) CR20160030A (xx)
CU (1) CU24352B1 (xx)
CY (1) CY1121247T1 (xx)
DK (1) DK3024826T3 (xx)
DO (1) DOP2016000009A (xx)
EA (1) EA032301B1 (xx)
ES (1) ES2711371T3 (xx)
FR (1) FR3008977A1 (xx)
GE (1) GEP20207070B (xx)
HK (2) HK1218754A1 (xx)
HR (1) HRP20190277T1 (xx)
HU (1) HUE041443T2 (xx)
IL (1) IL243449A0 (xx)
JO (1) JO3457B1 (xx)
LT (1) LT3024826T (xx)
MA (1) MA38801B1 (xx)
MD (1) MD4793C1 (xx)
ME (1) ME03346B (xx)
MX (1) MX365373B (xx)
MY (1) MY193619A (xx)
NI (1) NI201600016A (xx)
NZ (1) NZ716155A (xx)
PE (1) PE20160241A1 (xx)
PH (1) PH12016500034B1 (xx)
PL (1) PL3024826T3 (xx)
PT (1) PT3024826T (xx)
RS (1) RS58344B1 (xx)
RU (1) RU2689305C2 (xx)
SA (1) SA516370439B1 (xx)
SG (1) SG11201600205XA (xx)
SI (1) SI3024826T1 (xx)
TN (1) TN2016000003A1 (xx)
TR (1) TR201819155T4 (xx)
TW (1) TWI560184B (xx)
UA (1) UA117490C2 (xx)
UY (1) UY35664A (xx)
WO (1) WO2015011164A1 (xx)
ZA (1) ZA201600198B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017252546B2 (en) 2016-04-20 2021-07-29 Bristol-Myers Squibb Company Substituted bicyclic heterocyclic compounds
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
TW202342469A (zh) 2022-02-24 2023-11-01 法商施維雅藥廠 5—[7—(3,4—二氫—1h—異喹啉—2—羰基)—1,2,3,4—四氫異喹啉—6—基]—1h—吡咯—3—甲醯胺衍生物、包含其之醫藥組合物及其作為促細胞凋亡劑之用途
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
CA2596522A1 (en) * 2005-02-15 2006-08-24 Novo Nordisk A/S 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
AU2008242983B2 (en) 2007-04-16 2013-07-11 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
US7984530B2 (en) 2008-02-14 2011-07-26 Tory Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
BR112014015322A8 (pt) * 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
KR101682779B1 (ko) 2011-12-27 2016-12-05 인텔 코포레이션 게이팅된 도메인의 부하 조건들에 기초하여 게이팅된 도메인의 활성 상태 동안 전력 게이트들을 제어하기 위한 방법들 및 시스템들
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
FR3008977A1 (fr) 2015-01-30
UY35664A (es) 2015-01-30
UA117490C2 (uk) 2018-08-10
TWI560184B (en) 2016-12-01
US11028070B2 (en) 2021-06-08
LT3024826T (lt) 2019-02-25
US20200262816A1 (en) 2020-08-20
MD20160018A2 (ro) 2016-07-31
JP6395829B2 (ja) 2018-09-26
RU2016106003A (ru) 2017-08-28
HK1222856A1 (zh) 2017-07-14
MA38801A1 (fr) 2018-05-31
EA201600122A1 (ru) 2016-07-29
WO2015011164A1 (en) 2015-01-29
US9809574B2 (en) 2017-11-07
JO3457B1 (ar) 2020-07-05
CN105431422A (zh) 2016-03-23
MD4793C1 (ro) 2022-09-30
US20180002313A1 (en) 2018-01-04
MD4793B1 (ro) 2022-02-28
HRP20190277T1 (hr) 2019-04-05
DOP2016000009A (es) 2016-03-15
SA516370439B1 (ar) 2019-06-27
TR201819155T4 (tr) 2019-01-21
KR20160033224A (ko) 2016-03-25
CL2016000148A1 (es) 2016-08-12
CU20160010A7 (es) 2016-06-29
JP2016525529A (ja) 2016-08-25
MX365373B (es) 2019-05-31
BR112016001080B1 (pt) 2022-04-05
CA2919572A1 (en) 2015-01-29
AU2014295101A1 (en) 2016-02-04
CR20160030A (es) 2016-03-09
RU2689305C2 (ru) 2019-05-27
DK3024826T3 (en) 2019-03-04
MX2016000904A (es) 2016-04-25
CY1121247T1 (el) 2020-05-29
AU2014295101B2 (en) 2018-05-31
AP2016008989A0 (en) 2016-01-31
AR097009A1 (es) 2016-02-10
PH12016500034A1 (en) 2016-03-28
MA38801B1 (fr) 2019-03-29
GEP20207070B (en) 2020-02-25
PE20160241A1 (es) 2016-04-30
CN105431422B (zh) 2019-08-30
BR112016001080A2 (xx) 2017-07-25
NI201600016A (es) 2016-02-11
CA2919572C (en) 2017-06-20
HK1218754A1 (zh) 2017-03-10
MY193619A (en) 2022-10-20
TN2016000003A1 (en) 2017-07-05
CN109456324A (zh) 2019-03-12
NZ716155A (en) 2019-05-31
SG11201600205XA (en) 2016-02-26
ZA201600198B (en) 2019-07-31
ES2711371T3 (es) 2019-05-03
EP3024826B1 (en) 2018-11-14
EA032301B1 (ru) 2019-05-31
IL243449A0 (en) 2016-02-29
PT3024826T (pt) 2019-01-28
CN109456324B (zh) 2022-04-22
US20160194304A1 (en) 2016-07-07
SI3024826T1 (sl) 2019-03-29
PH12016500034B1 (en) 2016-03-28
PL3024826T3 (pl) 2019-05-31
RS58344B1 (sr) 2019-03-29
TW201504228A (zh) 2015-02-01
US10689364B2 (en) 2020-06-23
ME03346B (me) 2019-10-20
KR102008431B1 (ko) 2019-08-07
HUE041443T2 (hu) 2019-05-28
EP3024826A1 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
CU24352B1 (es) DERIVADOS DE ISOINDOLINA O ISOQUINOLINA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS DE Bcl-2 EN EL TRATAMIENTO DE CÁNCERES Y ENFERMEDADES AUTOINMUNES Y DEL SISTEMA INMUNITARIO, Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2017000804A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
CL2017002452A1 (es) Nuevos compuestos bicíclicos
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP14008606A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20160011A7 (es) Derivados de tetrahidroisoquinolina útiles como inhibidores bcl-2 antiapoptóticos y composiciones farmacéuticas que los contienen
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
NI201400080A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
BR112015029216A2 (pt) tratamento de vasculopatia coroidal polipoidal
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
UY34459A (es) Compuestos para tratamiento y prevención de adherencias, composiciones farmacéuticas relacionadas c on los compuestos y métodos para la prevención y tratamiento de adherencias
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr